NCT00274144View on ClinicalTrials.gov

Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

March 31, 2004

Study Completion Date

May 31, 2004

Conditions
HypertensionCoronary Arteriosclerosis
Interventions
DRUG

telmisartan 40 mg

DRUG

placebo 40 mg

Trial Locations (1)

66421

Universitätsklinik des Saarlandes, Homburg/Saar

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY